Skip to main content
. 2017 Mar 21;23(11):2077–2085. doi: 10.3748/wjg.v23.i11.2077

Table 1.

Patient, tumor and treatment characteristics

Characteristic n Percent
Age (yr), median 54 (range, 32-75)
Sex Male 44 86.3
Female 7 13.7
Viral type B 44 86.3
C 4 7.8
NBNC 3 5.9
Child-Pugh class A 49 96.1
B 2 3.9
Modified UICC stage II 4 7.8
III 32 62.7
IV 15 29.5
BCLC stage A 14 27.5
B 12 23.5
C 25 49.0
PVT No 31 60.8
Yes 20 39.2
Multiplicity No 25 49.0
Yes 26 51.0
Tumor size in cm, median 8.5 (range, 1.0-19.6)
AFP (IU/mL), median 141.9 (range, 1.53-83000)
PIVKA-II (mAU/mL), median 600 (range, 12-2000)
Treatment-naïve Yes 29 56.9
No 22 43.1
Total dose of RT (Gy), median 50.4 (range, 45-64.8)

NBNC: Non-B non-C; UICC: International Union Against Cancer; BCLC: Barcelona Clinic Liver Cancer; PVT: Portal vein thrombosis; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: Radiotherapy.